Does the media favor NRXP or TLRY?

In the previous week, Tilray Brands had 14 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 24 mentions for Tilray Brands and 10 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.92 beat NRx Pharmaceuticals' score of -0.53 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative Tilray Brands 13 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RLMD or NRXP more profitable?

NRx Pharmaceuticals' return on equity of 0.00% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -59.03% -53.97% NRx Pharmaceuticals N/A N/A -202.92%

Does the media prefer RLMD or NRXP?

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 7 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.53 beat NRx Pharmaceuticals' score of -0.53 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media refer more to BIOA or NRXP?

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than BioAge Labs. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 6 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.31 beat NRx Pharmaceuticals' score of -0.53 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Is AQST or NRXP more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% NRx Pharmaceuticals N/A N/A -202.92%

Does the media prefer AQST or NRXP?

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 7 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.53 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor NRXP or OVID?

In the previous week, NRx Pharmaceuticals had 7 more articles in the media than Ovid Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 3 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.63 beat NRx Pharmaceuticals' score of -0.53 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Negative Ovid Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NRx Pharmaceuticals (NRXP) Competitors

$3.35 -0.23 (-6.42%)

As of 04:00 PM Eastern

Compare

NRXP vs. TLRY, RLMD, BIOA, AQST, and OVID

Should you buy NRx Pharmaceuticals stock or one of its competitors? NRx Pharmaceuticals's main competitors and comparable companies include Tilray Brands (TLRY), Relmada Therapeutics (RLMD), BioAge Labs (BIOA), Aquestive Therapeutics (AQST), and Ovid Therapeutics (OVID). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NRx Pharmaceuticals compare to Tilray Brands?

NRx Pharmaceuticals (NASDAQ:NRXP) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 929.85%. Tilray Brands has a consensus target price of $11.00, suggesting a potential upside of 148.87%. Given NRx Pharmaceuticals' higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

NRx Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	98.68	-$28.62M	-$1.09	N/A
Tilray Brands	$915.45M	0.66	-$121.40M	-$1.08	N/A

NRx Pharmaceuticals has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. NRx Pharmaceuticals' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Tilray Brands	-13.11%	-7.76%	-5.59%

In the previous week, Tilray Brands had 14 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 24 mentions for Tilray Brands and 10 mentions for NRx Pharmaceuticals. Tilray Brands' average media sentiment score of 0.92 beat NRx Pharmaceuticals' score of -0.53 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Tilray Brands	13 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

NRx Pharmaceuticals beats Tilray Brands on 9 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Relmada Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 7 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.53 beat NRx Pharmaceuticals' score of -0.53 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Relmada Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 164.32%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 929.85%. Given NRx Pharmaceuticals' higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NRx Pharmaceuticals has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
NRx Pharmaceuticals	$1.23M	98.68	-$28.62M	-$1.09	N/A

NRx Pharmaceuticals' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-59.03%	-53.97%
NRx Pharmaceuticals	N/A	N/A	-202.92%

Relmada Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, indicating that its stock price is 118% more volatile than the broader market.

Summary

Relmada Therapeutics beats NRx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

NRx Pharmaceuticals has lower revenue, but higher earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	58.46	-$80.61M	-$2.38	N/A
NRx Pharmaceuticals	$1.23M	98.68	-$28.62M	-$1.09	N/A

BioAge Labs presently has a consensus price target of $36.57, suggesting a potential upside of 219.40%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 929.85%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NRx Pharmaceuticals has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. NRx Pharmaceuticals' return on equity of 0.00% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than BioAge Labs. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 6 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.31 beat NRx Pharmaceuticals' score of -0.53 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

NRx Pharmaceuticals beats BioAge Labs on 10 of the 16 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 7 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.53 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative

NRx Pharmaceuticals has lower revenue, but higher earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	12.09	-$83.78M	-$0.61	N/A
NRx Pharmaceuticals	$1.23M	98.68	-$28.62M	-$1.09	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Aquestive Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 98.14%. NRx Pharmaceuticals has a consensus target price of $34.50, suggesting a potential upside of 929.85%. Given NRx Pharmaceuticals' higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Aquestive Therapeutics beats NRx Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

NRx Pharmaceuticals (NASDAQ:NRXP) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

In the previous week, NRx Pharmaceuticals had 7 more articles in the media than Ovid Therapeutics. MarketBeat recorded 10 mentions for NRx Pharmaceuticals and 3 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 0.63 beat NRx Pharmaceuticals' score of -0.53 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Ovid Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NRx Pharmaceuticals presently has a consensus target price of $34.50, indicating a potential upside of 929.85%. Ovid Therapeutics has a consensus target price of $5.71, indicating a potential upside of 118.10%. Given NRx Pharmaceuticals' higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Ovid Therapeutics has higher revenue and earnings than NRx Pharmaceuticals. Ovid Therapeutics is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	98.68	-$28.62M	-$1.09	N/A
Ovid Therapeutics	$7.25M	67.45	-$17.41M	-$0.29	N/A

NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

NRx Pharmaceuticals has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. NRx Pharmaceuticals' return on equity of 0.00% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Ovid Therapeutics	-240.11%	-22.51%	-18.67%

Summary

Ovid Therapeutics beats NRx Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get NRx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXP vs. The Competition

Export

Metric	NRx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$121.37M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-3.07	788.52	269.75	24.74
Price / Sales	98.68	967.70	652.34	108.60
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	-6.20	10.33	11.27	6.42
Net Income	-$28.62M	$2.77B	$3.45B	$347.12M
7 Day Performance	3.40%	2.06%	3.57%	2.48%
1 Month Performance	-20.05%	-1.55%	-0.58%	-1.04%
1 Year Performance	32.94%	191.36%	77.53%	23.22%

NRx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXP NRx Pharmaceuticals	2.0581 of 5 stars	$3.35 -6.4%	$34.50 +929.9%	+42.1%	$121.37M	$1.23M	N/A	2	News Coverage Upcoming Earnings Analyst Forecast
TLRY Tilray Brands	4.3285 of 5 stars	$4.56 +2.6%	$11.00 +141.5%	-29.6%	$530.89M	$915.45M	N/A	2,842
RLMD Relmada Therapeutics	2.0408 of 5 stars	$5.02 -6.5%	$12.00 +139.0%	+741.0%	$528.12M	N/A	N/A	10	Earnings Report
BIOA BioAge Labs	3.1936 of 5 stars	$11.68 +3.6%	$36.57 +213.1%	+170.7%	$519.18M	$8.99M	N/A	N/A	Earnings Report
AQST Aquestive Therapeutics	1.6233 of 5 stars	$3.91 -0.4%	$8.50 +117.7%	+1.0%	$489.96M	$44.54M	N/A	160	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXP) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. TLRY, RLMD, BIOA, AQST, and OVID

How does NRx Pharmaceuticals compare to Tilray Brands?

Summary

How does NRx Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does NRx Pharmaceuticals compare to BioAge Labs?

Summary

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

Summary

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NRx Pharmaceuticals (NRXP) Competitors

NRXP vs. TLRY, RLMD, BIOA, AQST, and OVID

How does NRx Pharmaceuticals compare to Tilray Brands?

Do analysts rate NRXP or TLRY?

Which has stronger valuation & earnings, NRXP or TLRY?

Which has more risk & volatility, NRXP or TLRY?

Is NRXP or TLRY more profitable?

Does the media favor NRXP or TLRY?

Do insiders & institutionals hold more shares of NRXP or TLRY?

Summary

How does NRx Pharmaceuticals compare to Relmada Therapeutics?

Does the media prefer RLMD or NRXP?

Do analysts rate RLMD or NRXP?

Do insiders and institutionals have more ownership in RLMD or NRXP?

Which has stronger earnings and valuation, RLMD or NRXP?

Is RLMD or NRXP more profitable?

Which has more risk and volatility, RLMD or NRXP?

Summary

How does NRx Pharmaceuticals compare to BioAge Labs?

Which has more volatility & risk, BIOA or NRXP?

Which has stronger earnings & valuation, BIOA or NRXP?

Do analysts prefer BIOA or NRXP?

Do insiders & institutionals have more ownership in BIOA or NRXP?

Is BIOA or NRXP more profitable?

Does the media refer more to BIOA or NRXP?

Summary

How does NRx Pharmaceuticals compare to Aquestive Therapeutics?

Which has more risk and volatility, AQST or NRXP?

Is AQST or NRXP more profitable?

Does the media prefer AQST or NRXP?

Which has preferable earnings & valuation, AQST or NRXP?

Do insiders & institutionals have more ownership in AQST or NRXP?

Do analysts prefer AQST or NRXP?

Summary

How does NRx Pharmaceuticals compare to Ovid Therapeutics?

Does the media favor NRXP or OVID?

Do analysts prefer NRXP or OVID?

Which has higher valuation and earnings, NRXP or OVID?

Which has more risk and volatility, NRXP or OVID?

Do institutionals and insiders believe in NRXP or OVID?

Is NRXP or OVID more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXP vs. The Competition

NRx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools